CompletedPhase 2NCT00072007

Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Swiss Cancer Institute
Principal Investigator: Reinhard Zenhaeusern, MD
Insel Gruppe AG, University Hospital Bern
Intervention: filgrastim(biological)
Enrollment: 43 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2002 – 2010

Study locations (11)

Kantonspital Aarau, Aarau, Switzerland
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Inselspital Bern, Bern, Switzerland
Spitaeler Chur AG, Chur, Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Kantonsspital, Luzerne, Luzerne, Switzerland
Hopital des Cadolles, Neuchatel, Neuchâtel, Switzerland
Praxis Dr. Beretta, Rheinfelden, Switzerland
Kantonsspital - St. Gallen, Sankt Gallen, Switzerland
Onkozentrum, Zurich, Switzerland
UniversitaetsSpital Zuerich, Zurich, Switzerland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00072007 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials